Image Place holder

Sepideh Mokhtari, MD


Specialty: Neurology
Program: Neuro-Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Meningioma , Neurofibromatosis , Brain Cancer , Glioblastoma

Dr. Sepideh Mokhtari is an Associate Member in the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Mokhtari received her MD from Texas A&M College of Medicine in Temple, TX. She completed a Neurology Residency at Houston Methodist Hospital, where she also served as Chief Resident. She most recently completed a Neuro-Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Mokhtari’s clinical interests are primarily in brain tumors and neurologic complications of cancer. Her research focus is the quality of care for cancer patients with neurologic complications and primary brain tumors. In addition, her research interests include patients with meningioma and glioblastoma with or without other neurologic illness.

Education & Training

Board Certification:

  • Neurology
  • Psychiatry
  • Neuro-Oncology

Fellowship:

  • Memorial Sloan Kettering Cancer Center - Neuro-Oncology

Residency:

  • Houston Methodist Hospital - Neurology

Medical School:

  • Texas A&M - MD
Participating Trials

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 19339
A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases
Condition: Neurologic Oncology
Intervention: AZD9291 (Osimertinib); Avastin (Bevacizumab); Bevacizumab
Open

CLINICAL TRIAL 19587
Neurofibroma and MPNST Tumor Progression in Neurofibromatosis Type 1 (NF1) -- Genomic, Histological and Clinical Analysis, an NF Research MPNST Genomic Consortium (GeM) Project: Part 2 -- Prospective Recruitment, Tissue Collection, and Analysis
Condition: Neurologic Oncology
Intervention:
Open

CLINICAL TRIAL 19327
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18661
Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined with Nivolumab, Ipilimumab and Bevacizumab in Patients with Recurrent High Grade Gliomas
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); BMS-936558 (Nivolumab); Bevacizumab; Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19648
Phase IB Study of Avelumab with Radiotherapy in Patients with Leptomeningeal Disease
Condition: Neurologic Oncology
Intervention: Avelumab; MSB00100718C (Avelumab)
Open

CLINICAL TRIAL 19956
A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Condition: Neurologic Oncology
Intervention: CB-839; Temodal (Temozolomide); Temozolomide
Open

CLINICAL TRIAL 19342
A Phase I Trial of Pembrolizumab and Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
Condition: Neurologic Oncology
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Temodal (Temozolomide); Temozolomide; Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 19970
A Pilot Trial of Intratumorally-Administered Topotecan using Convection-Enhanced Delivery (CED) in Patients with Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)
Condition: Neurologic Oncology
Intervention: Topotecan
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019 Jun;175(3):781-788. Pubmedid: 30859348.
  • B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun;169(2):391-396. Pubmedid: 29392582.
  • Sahebjam S, Stallworth DG, Mokhtari S, Tran ND, Arrington JA. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors. Cancer Control. 2017 Apr;24(2):180-186. Pubmedid: 28441372.